- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Myopic choroidal neovascularisation (myopic CNV) is one of the most feared complications of myopia, characterised by abnormal blood vessels that grow under the macula and affect the centre of the vision. While myopic CNV is historically thought to only occur in eyes with pathological myopia, it is now recognised that myopic CNV can occur at any degree of myopia and in eyes without typical myopic degenerative fundus changes.
Showing all 3 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
PIGF , VEGF-A |
Fusion protein |
Eylea® |
40 mg/mL |
– |
0,8 mg |
-80°C |
2021.11 |
627,00 € |
||
PIGF , VEGF-A |
Fusion protein |
Eylea® |
40 mg/mL |
– |
0,8 mg |
-80°C |
2025.02 |
1.296,00 € |
||
VEGF |
Biosimilar , Monoclonal Antibody |
Ximluci® |
10 mg/mL |
– |
0,21 mg |
tba |
tba |
680,00 € |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany